You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HCRU exacerbations

Showing 1 - 25 of 1,079
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Observing Severe Asthma in Patients Treated With Tezepelumab

Recruiting
  • Asthma
  • None (Observational Study)
  • Toronto, Ontario, Canada
    Research Site
Jan 23, 2023

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (CSJ117, Placebo)

Recruiting
  • Pulmonary Disease, Chronic Obstructive
  • Andalusia, Alabama
  • +59 more
Jul 29, 2022

Real-world Use of Benralizumab in Severe Eosinophilic Asthma in

Active, not recruiting
  • Severe Asthma
    • Bruxelles, Belgium
    • +9 more
    Feb 22, 2022

    Capture Clinical and Patient Centered Outcomes in Severe

    Recruiting
    • Severe Eosinophilic Asthma
    • Alexandroupolis, Greece
    • +15 more
    Aug 5, 2022

    Real-life After Initation of Treatment With Trixeo

    Not yet recruiting
    • Chronic Obstructive Pulmonary Disease
    • BGF (budesonide/glycopyrrolate/formoterol fumarate)
    • Acquaviva delle Fonti, Italy
    • +23 more
    May 8, 2023

    Healthcare Resource Use Among COVID-19 Patients Receiving

    Not yet recruiting
    • Covid-19
    • nirmatrelvir, ritonavir
    • Riyadh, Saudi Arabia
      Saudi Arabia
    Aug 25, 2023

    IMPACT of AspireSR® for VNS Therapy on Healthcare Resource

    Suspended
    • Epilepsy
      • Birmingham, United Kingdom
        Queen Elizabeth Hospital Birmingham
      Jul 27, 2023

      Burden of Disease and Outcomes in Chinese Patients on Peritoneal

      Completed
      • Anemia
        • Beijing, Beijing, China
          Peking University First Hospital
        Dec 27, 2022

        Heart Failure; With Decompensation Trial in United States (Danger Signs of Heart Failure Videos)

        Completed
        • Heart Failure; With Decompensation
        • Danger Signs of Heart Failure Videos
        • Macon, Georgia
        • +7 more
        Aug 11, 2022

        Healthcare Resource Utilization in Adults Diagnosed With Acute

        Completed
        • Acute Myeloid Leukemia (AML)
        • Helsinki, Finland
          Novartis Investigative Site
        Aug 3, 2022

        Adults With Severe Eosinophilic Asthma on Benralizumab.

        Active, not recruiting
        • Severe Eosinophilic Asthma
        • Survey Administration
        • Calgary, Alberta, Canada
        • +19 more
        Dec 1, 2022

        Asthma With Frequent Acute Attacks Phenotype

        Not yet recruiting
        • Asthma
        • Observation of clinical indicators related to asthma
        • (no location specified)
        Sep 6, 2023

        Sacubitril/Valsartan Treated Adult Chronic Heart Failure

        Completed
        • Chronic Heart Failure
        • East Hanover, New Jersey
          Novartis Investigative Site
        Nov 11, 2022

        Reveal Patterns of Presentation, Management and Outcome of SCLC

        Recruiting
        • Lung Cancer
          • Dammam, Saudi Arabia
          • +2 more
          Jul 25, 2022

          Anticoagulation in Venous Thromboembolism and Cancer

          Active, not recruiting
          • Neoplasms
          • Embolism
          • London, United Kingdom
            Pfizer Investigational Site
          Nov 17, 2022

          Healthcare Resources and Costs of Attention Deficit

          Completed
          • Attention Deficit Hyperactivity Disorder (ADHD)
          • No intervention
          • London, United Kingdom
            IQVIA Ltd
          Jul 11, 2022

          COPD Trial in Monastir (Telemonitoring)

          Recruiting
          • COPD
          • Telemonitoring
          • Monastir, Tunisia
            Khaoula Bel Haj Ali
          Nov 11, 2023

          HFNC in Management of Bronchiectasis Exacerbation

          Not yet recruiting
          • Bronchiectasis
          • bi-level ventillation
          • (no location specified)
          Feb 21, 2023

          Burden of Respiratory Syncytial Virus in Sweden: A Retrospective

          Active, not recruiting
          • Respiratory Syncytial Virus (RSV)
            • (no location specified)
            Nov 10, 2022

            Pulmonary Disease, Chronic Obstructive Trial (health education, Mobile application (Creating a WhatsApp group):, Home visit:)

            Not yet recruiting
            • Pulmonary Disease, Chronic Obstructive
            • health education
            • +3 more
            • (no location specified)
            Feb 14, 2023

            Based on Health Insurance Data About Treatment of Been Newly

            Completed
            Has Results
            • Pulmonary Disease, Chronic Obstructive
              • Wismar, Germany
                Institute for pharmacoeconomics and pharmaceutical logistics e.V
              Feb 10, 2022

              Pulmonary Disease, Chronic Obstructive Trial in Worldwide (Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100

              Terminated
              Has Results
              • Pulmonary Disease, Chronic Obstructive
              • Placebo ELLIPTA
              • +7 more
              • Mobile, Alabama
              • +161 more
              Jul 13, 2021

              Acute Exacerbation of COPD Trial in Beijing (Programmed Weaning From Noninvasive Mechanical Ventilation)

              Recruiting
              • Acute Exacerbation of COPD
              • Programmed Weaning From Noninvasive Mechanical Ventilation
              • Beijing, Beijing, China
                Peking University Third Hospita
              Aug 25, 2023

              Pulmonary Disease, Chronic Obstructive Trial in Worldwide (Danirixin, Danirixin matching , Standard of care)

              Completed
              Has Results
              • Pulmonary Disease, Chronic Obstructive
              • Birmingham, Alabama
              • +63 more
              Oct 6, 2020

              FODEPOC Study: Fat-free Mass Index in Copd

              Not yet recruiting
              • Chronic Obstructive Pulmonary Disease
              • Bioelectrical impedance analysis
              • (no location specified)
              May 2, 2023